BIOMAT Database Logo BIOMAT Database Logo

Single-Dose Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy. 2021

Martijn Beudel, and Fleur Rövekamp, and Diederik van de Beek, and Matthijs Brouwer
From the Department of Neurology (M. Beudel, D.v.d.B., M. Brouwer), Amsterdam Neuroscience Institute, Amsterdam University Medical Centers, the Netherlands; and Department of Neurology (F.R.), Northwest Hospitals, Alkmaar, the Netherlands. m.beudel@amsterdamumc.nl.

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D007968 Leukoencephalopathy, Progressive Multifocal An opportunistic viral infection of the central nervous system associated with conditions that impair cell-mediated immunity (e.g., ACQUIRED IMMUNODEFICIENCY SYNDROME and other IMMUNOLOGIC DEFICIENCY SYNDROMES; HEMATOLOGIC NEOPLASMS; IMMUNOSUPPRESSION; and COLLAGEN DISEASES). The causative organism is JC Polyomavirus (JC VIRUS) which primarily affects oligodendrocytes, resulting in multiple areas of demyelination. Clinical manifestations include DEMENTIA; ATAXIA; visual disturbances; and other focal neurologic deficits, generally progressing to a vegetative state within 6 months. (From Joynt, Clinical Neurology, 1996, Ch26, pp36-7) Encephalitis, JC Polyomavirus,Progressive Multifocal Leukoencephalopathy,JC Polyomavirus Encephalopathy,Encephalopathies, JC Polyomavirus,Encephalopathy, JC Polyomavirus,JC Polyomavirus Encephalitis,Leukoencephalopathies, Progressive Multifocal,Multifocal Leukoencephalopathies, Progressive,Multifocal Leukoencephalopathy, Progressive,Progressive Multifocal Leukoencephalopathies
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D061067 Antibodies, Monoclonal, Humanized Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab. Antibodies, Humanized,Humanized Antibodies

Related Publications

Martijn Beudel, and Fleur Rövekamp, and Diederik van de Beek, and Matthijs Brouwer
Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy.
April 2019, The New England journal of medicine,
Martijn Beudel, and Fleur Rövekamp, and Diederik van de Beek, and Matthijs Brouwer
Treatment of Progressive Multifocal Leukoencephalopathy with Pembrolizumab.
April 2019, The New England journal of medicine,
Martijn Beudel, and Fleur Rövekamp, and Diederik van de Beek, and Matthijs Brouwer
Stabilization of Progressive Multifocal Leukoencephalopathy After Pembrolizumab Treatment.
July 2020, The Neurohospitalist,
Martijn Beudel, and Fleur Rövekamp, and Diederik van de Beek, and Matthijs Brouwer
PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy.
January 2021, Therapeutic advances in neurological disorders,
Martijn Beudel, and Fleur Rövekamp, and Diederik van de Beek, and Matthijs Brouwer
Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy in China.
December 2023, Journal of neurovirology,
Martijn Beudel, and Fleur Rövekamp, and Diederik van de Beek, and Matthijs Brouwer
Successful treatment of HIV-associated progressive multifocal leukoencephalopathy with pembrolizumab.
March 2022, AIDS (London, England),
Martijn Beudel, and Fleur Rövekamp, and Diederik van de Beek, and Matthijs Brouwer
Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency.
November 2019, Neurology(R) neuroimmunology & neuroinflammation,
Martijn Beudel, and Fleur Rövekamp, and Diederik van de Beek, and Matthijs Brouwer
Sequential treatment of progressive multifocal leukoencephalopathy with intravenous immunoglobulins and pembrolizumab.
April 2022, Journal of neurovirology,
Martijn Beudel, and Fleur Rövekamp, and Diederik van de Beek, and Matthijs Brouwer
Pembrolizumab treatment of inflammatory progressive multifocal leukoencephalopathy: a report of two cases.
February 2022, Journal of neurovirology,
Martijn Beudel, and Fleur Rövekamp, and Diederik van de Beek, and Matthijs Brouwer
Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy.
January 2022, Emerging infectious diseases,
Copied contents to your clipboard!